Prior notification of a concentration

(Case M.9517 — Mylan/Upjohn)

(Text with EEA relevance)

(2020/C 72/10)

1. On 28 February 2020, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]).

This notification concerns the following undertakings:

— Mylan N.V. ('Mylan', the Netherlands),

— Upjohn Inc. ('Upjohn', China), controlled by Pfizer Inc. ('Pfizer', USA).

Mylan and Upjohn enter into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation by way of several transaction steps, including the transfer of shares and assets.

2. The business activities of the undertakings concerned are:

— for Mylan: Mylan develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals in addition to over-the-counter and consumer healthcare products.

— for Upjohn: Upjohn is a business division of Pfizer which operates a portfolio of off-patent branded and generic medicines, as well as a generic business in the United-States under Greenstone LLC.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9517 – Mylan/Upjohn

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

([1]) OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').